A new report from the Institute of Medicine (IOM) recommends that 8 preventive health services for women will be added to the services that health plans will cover at no cost to patients under the Patient Protection and Affordable Care Act of 2010 (PPACA).
A new report from the Institute of Medicine (IOM) recommends that 8 preventive health services for women be added to the services that health plans will cover at no cost to patients under the Patient Protection and Affordable Care Act of 2010 (ACA).
The ACA requires plans to cover the services listed in the U.S. Department of Health and Human Services' (HHS) comprehensive list of preventive services. At the agency's request, an IOM committee identified critical gaps in preventive services for women as well as measures that will further ensure women's health and well-being.
The recommendations are based on a review of existing guidelines and an assessment of the evidence on the effectiveness of different preventive services. The committee identified diseases and conditions that are more common or more serious in women than in men or for which women experience different outcomes or benefit from different interventions. The report suggests the following additional services:
• Screening for gestational diabetes
• Human papillomavirus (HPV) testing as part of cervical cancer screening for women over aged 30
• Counseling on sexually transmitted infections
• Counseling and screening for HIV
• Contraceptive methods and counseling to prevent unintended pregnancies
• Lactation counseling and equipment to promote breast-feeding
• Screening and counseling to detect and prevent interpersonal and domestic violence
• Yearly well-woman preventive care visits to obtain recommended preventive services
“These latest recommendations from the IOM should be welcomed and applauded by our healthcare industry given the well-recognized outcomes which may be derived from greater access to such services,” said David Calabrese, vice president, Clinical Operations, MedMetrics Health Partners, an SXC Company.
For example, the health and financial impact of intimate partner violence (IPV) is vast and widespread, indicating that any plan designed to strengthen screening and intervention efforts is a welcome addition, said Jeff R. Temple, PhD, an assistant professor and psychologist in the department of obstetrics and gynecology at University of Texas Medical Department (UTMB Health), Galveston, Texas. Indeed, a report by the Centers for Disease Control and Prevention estimated that IPV results in more than $4 billion a year in healthcare services.
“However, given recent research showing that screening for IPV may not, in and of itself, result in improved violence outcomes, a concomitant investment should also be made in enhancing the quality, availability, and utilization of services offered to abused women,” Temple told Drug Topics.
“A concerted effort should be made to prevent potential early predictors of intimate partner violence, such as bullying and teen dating violence. While initially costly, attending to these abusive behaviors in our youth would not only result in healthier adult relationships, but would have the potential to save a substantial amount of healthcare dollars in the long run,” he said. “Further, we should not overlook the role of perpetrators. Efforts to screen and offer evidenced-based interventions to men and women who commit acts of partner violence should be strengthened.”
“From a pharmacy perspective, our nation's pharmacists are once again in an ideal position to assist in reinforcing these efforts, as many are focused in areas of women's health that are familiar to our profession,” Calabrese added. “We also have the greatest degree of direct interaction with the patient community, thus providing yet another opportunity for us to demonstrate our value in further driving a higher-quality, more cost-efficient healthcare system for all."
HHS's guidelines on preventive health services for women will need to be updated routinely in light of new science. As part of this process, the report said that HHS should establish a commission to recommend which services health plans should cover. The commission should be separate from the groups that assess evidence of health services' effectiveness, and it should consider cost-effectiveness analyses, evidence reviews, and other information to make coverage recommendations.
The report addresses concerns that the current guidelines on preventive services contain gaps when it comes to women's needs. Women suffer disproportionate rates of chronic disease and disability from some conditions. Because they need to use more preventive care than men on average due to reproductive and gender-specific conditions, they face higher out-of-pocket costs, the report noted.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.